TD Waterhouse Canada Inc. Makes New $1.59 Million Investment in Definium Therapeutics, Inc. $DFTX

Key Points

• TD Waterhouse Canada acquired 36,694 shares of Definium Therapeutics valued at approximately $1.59 million, while institutional investors and hedge funds collectively own 27.91% of the company.
• Wall Street sentiment remains broadly positive: analysts assign the stock an average “Buy” rating with a consensus price target of $63, including targets as high as $75.
• Definium reported a quarterly loss of $1.44 per share, missing estimates by $0.89, while insiders sold 67,119 shares worth roughly $2.89 million over the last quarter.

TD Waterhouse Canada Inc. bought a new position in Definium Therapeutics, Inc. (NASDAQ:DFTX - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 36,694 shares of the company's stock, valued at approximately $1,592,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Russell Investments Group Ltd. lifted its stake in Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company's stock worth $25,000 after purchasing an additional 2,003 shares during the last quarter. Nykredit A S bought a new position in shares of Definium Therapeutics in the 2nd quarter worth about $45,000. BNP Paribas Financial Markets boosted its holdings in shares of Definium Therapeutics by 56.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company's stock valued at $55,000 after buying an additional 3,020 shares during the period. Caxton Associates LLP bought a new stake in shares of Definium Therapeutics during the 3rd quarter valued at about $126,000. Finally, ExodusPoint Capital Management LP bought a new position in Definium Therapeutics in the fourth quarter worth about $254,000. 27.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Oppenheimer restated an "outperform" rating and issued a $70.00 target price on shares of Definium Therapeutics in a research note on Wednesday, August 12th. Leerink Partners set a $52.00 price objective on Definium Therapeutics and gave the company an "outperform" rating in a research report on Monday, June 22nd. Robert W. Baird increased their target price on Definium Therapeutics from $57.00 to $75.00 and gave the stock an "outperform" rating in a research report on Thursday, August 13th. Needham & Company LLC increased their target price on Definium Therapeutics from $50.00 to $66.00 and gave the stock a "buy" rating in a research report on Wednesday, August 12th. Finally, Canaccord Genuity Group set a $64.00 target price on Definium Therapeutics and gave the company a "buy" rating in a research note on Thursday, August 13th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Definium Therapeutics presently has an average rating of "Buy" and a consensus price target of $63.00.

Insiders Place Their Bets

In other news, insider Mark Sullivan sold 13,008 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $585,750.24. Following the completion of the transaction, the insider owned 320,571 shares of the company's stock, valued at approximately $14,435,312.13. This represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Robert Barrow sold 29,208 shares of the firm's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $1,315,236.24. Following the transaction, the chief executive officer directly owned 1,098,246 shares in the company, valued at $49,454,017.38. This trade represents a 2.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 67,119 shares of company stock worth $2,887,496. Insiders own 2.40% of the company's stock.

Definium Therapeutics Price Performance

Shares of NASDAQ:DFTX opened at $38.23 on Wednesday. The firm's 50 day moving average is $43.35 and its two-hundred day moving average is $29.88. The firm has a market capitalization of $5.14 billion, a P/E ratio of -11.15 and a beta of 2.23. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. Definium Therapeutics, Inc. has a 52 week low of $8.77 and a 52 week high of $49.70.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Analysts anticipate that Definium Therapeutics, Inc. will post -3.02 earnings per share for the current year.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.